Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: Quantitation by direct probe chemical ionization mass spectrometry
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
This study was performed to define the amounts of methadone and metabolites excreted in urine in otherwise healthy maintenance patients, and to determine whether the metabolism and elimination of methadone, as assessed by analyses of urines, is altered in patients with liver disease. A method was developed for the simultaneous quantitation of methadone and six of its major and minor metabolites using chemical ionization mass spectrometry with direct probe introduction to increase sensitivity for analyses of the minor metabolites. Analyses of urine from unmedicated volunteers showed that the interferences at the mass range of interest (264-326) were usually small and therefore would not introduce significant error into analysis. Nineteen patients well-stabilized in chronic long-term methadone treatment were studied, five otherwise healthy males and fourteen patients with chronic liver disease (nine males and four females). Twenty-four hour urine collections were made and analyzed following extraction procedures. The concentrations of methadone and the major pyrrolidine metabolite exceeded 1 microgram ml-1 in all cases; the concentration (listed in descending order) of pyrrolidone, pyrroline, hydroxymethadone, hydroxypyrroline, methadol and hydroxypyrrolidine were all less than 1 microgram ml-1. The total 24 hour urinary excretion of methadone and its metabolites was 48.3% (+/- 1.71 SEM) in otherwise healthy patients but was significantly lower, 32.6% (+/- 3.19 SEM) in patients with liver disease (p less than 0.05). The total 24 hour excretion of the pyrrolidone metabolite, the end product of two pathways of methadone metabolism, was also significantly reduced in patients with liver disease (p less than 0.05). Females with liver disease had significantly higher ratios of pyrrolidine to methadone than did males with liver disease (p less than 0.05).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Decreased hepatic metabolism and plasma protein can lead to increased methadone clearance.132”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [132]
Citations
Cites
Protein Binding and Kinetics of Drugs in Liver Diseases
Blaschke, T. F. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702010-00003 · Cited by 264
Medical safety and side effects of methadone in tolerant individuals
Kreek, M. J. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220060039009 · Cited by 247
Self-citationThe effect of cirrhosis on the disposition and elimination of meperidine in man
Klotz, U., McHorse, T. S., Wilkinson, G. R., & Schenker, S. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974164667 · Cited by 165
MEDICAL COMPLICATIONS IN METHADONE PATIENTS*
Kreek, M. J. (1978) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1978.tb16769.x · Cited by 156
Self-citationThe Effect of Disease States on Drug Pharmacokinetics
Hull, J. H. (1977) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/34.9.992b · Cited by 156
Morphine tolerance in hepatic cirrhosis
Laidlaw, J., Read, A. E., & Sherlock, S. (1961) · Gastroenterology · doi:10.1016/s0016-5085(61)80071-1 · Cited by 137
Long-Term Methadone Maintenance Therapy: Effects on Liver Function
KREEK, M. J., DODES, L., KANE, S., KNOBLER, J., & MARTIN, R. (1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-77-4-598 · Cited by 120
Self-citationUrinary metabolites of DL-methadone in maintenance subjects
Sullivan, H. R., & Due, S. L. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00266a009 · Cited by 109
Drug Disposition and Liver Disease
Wilkinson, G. R., & Schenker, S. (1975) · Drug Metabolism Reviews · doi:10.3109/03602537508993754 · Cited by 106
DRUG INTERACTIONS WITH METHADONE*
Kreek, M. J., Gutjahr, C. L., Garfield, J. W., Bowen, D. V., & Field, F. H. (1976) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1976.tb27945.x · Cited by 91
Self-citation
Research works printed but not linked: 7
- Bond, 1978, Am. J. Hosp. Pharm., 35, 406
- Closson, 1977, Am. J. Hosp. Pharm., 34, 520
- Kreek, 1973, N. Y. State J. Med., 23, 2773
- Weinkam, 1976, Anal. Biochem., 48, 203
- Tong, 1979, Clin. Pharmacol. Ther., 25, 242
- Harte, 1976, Clin. Res., 24, 623a
- Bowen, 1978, Adv. Mass Spectrom., 7B, 1634
Cited by
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
“132 Increased methadone clearance may result in onset of withdrawal symptoms and can be prevented by increasing methadone dose.”
BackgroundPharmacokinetics of Opioids in Liver Disease
Tegeder, I., L??tsch, J., & Geisslinger, G. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937010-00002 · Cited by 306
Interindividual Variability of Methadone Response: Impact of Genetic Polymorphism
Li, Y., Kantelip, J., Schieveen, P. G., & Davani, S. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256276 · Cited by 135
Steady‐state pharmacokinetics of (R)‐ and (S)‐methadone in methadone maintenance patients
Foster, D. J. R., Somogyi, A. A., Dyer, K. R., White, J. M., & Bochner, F. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00272.x · Cited by 129
Pharmacotherapy in the Treatment of Addiction: Methadone
Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010) · Journal of Addictive Diseases · doi:10.1080/10550881003684798 · Cited by 108
“47 , 48 , 49 , 50 , 51 The amount of methadone excreted in the urine is modestly affected by urine acidity.”
Self-citationPharmacokinetics of methadone and its primary metabolite in 20 opiate addicts
de Vos, J. W., Ufkes, J. G. R., Wilgenburg, H. V., Geerlings, P. J., & van den Brink, W. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194951 · Cited by 98
Kreek, M. J. (1996) · Neurochemical Research · doi:10.1007/bf02532387 · Cited by 92
Self-citationPopulation pharmacokinetics of (R)‐, (S)‐ and rac‐methadone in methadone maintenance patients
Foster, D. J. R., Somogyi, A. A., White, J. M., & Bochner, F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02079.x · Cited by 75
Rich, R. L., & Myszka, D. G. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00025-8 · Cited by 72
Effect of Severe Alcoholic Liver Disease on the Disposition of Methadone in Maintenance Patients
Novick, D. M., Kreek, M. J., Ams, P. A., Lau, L. L., Yancovitz, S. R., & Gelb, A. M. (1985) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1985.tb05558.x · Cited by 56
Self-citationRudewicz, P. J., & Munson, B. (1986) · Analytical Chemistry · doi:10.1021/ac00295a004 · Cited by 43
Methadone and Metabolite Urine Concentrations in Patients Maintained on Methadone
Preston, K. L., Epstein, D. H., Davoudzadeh, D., & Huestis, M. A. (2003) · Journal of Analytical Toxicology · doi:10.1093/jat/27.6.332 · Cited by 41
Long-Term Pharmacotherapy for Opiate (Primarily Heroin) Addiction: Opioid Agonists
Kreek, M. J. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60963-3_14 · Cited by 39
Self-citationFoster, D. J. R., Somogyi, A. A., & Bochner, F. (2000) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00246-2 · Cited by 39
Shafer, S. L., & Flood, P. D. (2008) · Springer eBooks · doi:10.1007/978-0-387-72527-7_15 · Cited by 30
Kreek, M. J., Bencsath, F. A., Fanizza, A. M., & Field, F. H. (1983) · Journal of Mass Spectrometry · doi:10.1002/bms.1200101003 · Cited by 27
Self-citationKell, M. J. (1995) · Journal of Addictive Diseases · doi:10.1300/j069v14n01_09 · Cited by 22
Vos, J. W. D., vanWilgenburg, H., van den Brink, W., Kaplan, C. D., & de Vries, M. W. (1996) · Addiction Research & Theory · doi:10.3109/16066359609005243 · Cited by 13
Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency
Fraser, A. D. (1990) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30574-2 · Cited by 12
Opiate metabolism and excretion
Moore, R. A., Hand, C. W., & McQuay, H. J. (1987) · Baillière s Clinical Anaesthesiology · doi:10.1016/s0950-3501(87)80038-7 · Cited by 12
Borg, L., & Kreek, M. J. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2913-9_23 · Cited by 8
Self-citationMethadone Maintenance Treatment for Harm Reduction Approach to Heroin Addiction
Kreek, M. J. (1991) · Springer eBooks · doi:10.1007/978-3-7091-9173-6_19 · Cited by 7
Self-citationLucas, A. C. D. S., Bermejo, A. M., Tabernero, M. J., Fernández, P. F., & CÁMpora, P. (2001) · Addiction Biology · doi:10.1080/13556210020040253 · Cited by 6
Proceedings of an expert workshop on the induction and stabilisation of patients onto methadone
Humenuik, R., Ali, R. L., White, J. M., Hall, W., & Farrell, M. (2000) · Cited by 5
zie, Y. B., Talon, V. R., Louët, A. L., Illier, C., Billaud, E. M., Prognon, P., & Boutouyrie, P. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200406000-00009 · Cited by 5
Pharmacological Treatment of Addiction: Normalization of Physiology and AIDS Risk Reduction
Kreek, M. J. (1995) · Springer eBooks · doi:10.1007/978-3-7091-6901-8_19 · Cited by 3
Self-citationKang, G.-I. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0095598 · Cited by 2
Bart, G. B. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Einfluss des Cytochrom P450 Enzyms CYP2D6 auf den Metabolismus von Methadon
Schmid, D. (2008) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.9531 · Cited by 1
Estudo farmacocinético da metadona por via oral em cães
Crosignani, N. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Problems of Drug Dependence, 1987 : Proceedings of the 49th Annual Scientific Meeting
:None (1987) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-200604100200-4
Pain Management in Liver Transplantation
Weyker, P. D., Webb, C. A.-J., & Mathew, L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5167-9_35
Elkader, A. K. (2009) · TSpace (University of Toronto)
Conaway, C. C. (1990) · Elsevier eBooks · doi:10.1016/b978-0-444-81316-9.50048-7
Pain Management in Liver Transplantation
Weyker, P. D., Webb, C. A.-J., & Mathew, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-64298-7_39
Strategies for research on the interactions of drugs of abuse
:None (1986) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-200605290200-3
Metadata
- Authors
- Kreek, M. J., Bencsath, F. A., & Field, F. H.
- Affiliations
- Rockefeller University (US)
- ORCID
- Kreek, Mary Jeanne
- Venue
- Biological Mass Spectrometry
- Publisher
- Wiley
- Published
- 1980-09
- Volume
- 7
- Issue
- 9
- Pages
- 385-395
- ISSN
- 1076-5174 (ISSN-L)
- 1052-9306
- 1096-9888
- OpenAlex
- W2138745161
- Cited by
- 33
- References
- 35
- Citations by year
- 2018: 1 · 2013: 1 · 2012: 2
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 12783 d)
- Locations
- Journal of Mass Spectrometry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- methadone, methadone metabolites, chronic liver disease, urinary excretion, methadone maintenance treatment, pyrrolidinone, drug metabolism, elimination, sex differences, chemical ionization mass spectrometry
- MeSH terms
- Chronic Disease, Female, Heroin Dependence, Humans, Liver Diseases, Male, Methadone, Pyrrolidines, Sex Factors, Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.